Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

155
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
155
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

540
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
540
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

285
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
285
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

571
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
571
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

66
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
66

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Birthing balls to decrease labor pain and peanut balls to decrease length of labor: what is the evidence?

American journal of obstetrics and gynecology·2023
Same author

Binding Potassium to Improve Treatment With Renin-Angiotensin-Aldosterone System Inhibitors: Results From Multiple One-Stage Pairwise and Network Meta-Analyses of Clinical Trials.

Frontiers in medicine·2021
Same author

The Inhibition of Complement System in Formal and Emerging Indications: Results from Parallel One-Stage Pairwise and Network Meta-Analyses of Clinical Trials and Real-Life Data Studies.

Biomedicines·2020
Same author

Cholesterol-Lowering Treatment in Chronic Kidney Disease: Multistage Pairwise and Network Meta-Analyses.

Scientific reports·2019
Same author

[Educational environment in a Peruvian medical school. A negative trend over the academic years].

Revista medica de Chile·2018
Same author

[Psychometric analysis of a questionnaire to measure the educational environment in a sample of medical students in Peru].

Revista peruana de medicina experimental y salud publica·2017

Related Experiment Video

Updated: Mar 8, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

[Safety of statins].

Teodore J Oscanoa Espinoza1, Napoleon Paredes-Pérez2, Frank Lizaraso-Soto3

  • 1Instituto de Investigación de la Facultad de Medicina de la Universidad de San Martin de Porres. Sección Farmacología de la Universidad Nacional Mayor de San Marcos. Hospital Almenara, Departamento de Medicina Interna. Lima, Perú.

Revista De La Facultad De Ciencias Medicas (Cordoba, Argentina)
|February 3, 2017
PubMed
Summary
This summary is machine-generated.

Statins are crucial for preventing cardiovascular disease, but effectiveness varies little between them. Selection should prioritize safety and cost, considering risks like rhabdomyolysis and type 2 diabetes.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K
Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access
05:04

Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access

Published on: November 19, 2020

5.0K

Related Experiment Videos

Last Updated: Mar 8, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K
Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access
05:04

Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access

Published on: November 19, 2020

5.0K

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Safety

Background:

  • Statins are vital for cardiovascular disease prevention, targeting cholesterol.
  • Current evidence shows minimal differences in effectiveness among the 7 available statins regarding cardiovascular outcomes.
  • Patient-specific factors like safety and cost are increasingly important for statin selection.

Purpose of the Study:

  • To compare the safety profiles of different statins.
  • To highlight significant differences in adverse reactions between statins.
  • To inform clinical decisions regarding statin choice based on risk-benefit analysis.

Main Methods:

  • Meta-analysis of recent studies on statin effectiveness.
  • Review of reported adverse reactions, focusing on rhabdomyolysis and type 2 diabetes mellitus.
  • Comparative analysis of safety data across different statin medications.

Main Results:

  • No significant differences in cardiovascular morbidity and mortality reduction were found among statins.
  • Significant variations exist in the incidence of rhabdomyolysis and risk of type 2 diabetes mellitus among different statins.
  • Rhabdomyolysis led to the withdrawal of cerivastatin, underscoring safety concerns.

Conclusions:

  • Statin selection should move beyond efficacy to focus on individual safety profiles and cost-effectiveness.
  • Understanding differential risks of adverse events, such as rhabdomyolysis and type 2 diabetes, is crucial for personalized statin therapy.
  • Further research into comparative safety of statins is warranted to optimize patient care.